logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 

Equities – Your destination to connect with the growth investment community.
Gelesis (GLSS) is a biotechnology company focused on the development of first-in-class products to induce weight loss and improve glycemic control in overweight and obese patients, including those with prediabetes and type 2 diabetes. It is based in Boston, MA. Eleven other companies are scheduled for the week of May…
Read more...
MultiVir (MVIR) is a clinical-stage gene therapy company developing a pipeline of novel product candidates for the treatment of multiple oncological indications. It is based in Houston, TX. Eleven other companies are scheduled to IPO for the week of May 4. The full IPO calendar is available at IPO Premium.…
Read more...
HTG Molecular Diagnostics (HTGM) is a commercial stage company that developed and markets a novel technology platform to facilitate the routine use of complex molecular profiling. It is based in Tucson, AZ. Eleven other companies are scheduled to IPO for the week of May 4. The full IPO calendar is…
Read more...
May is National Stroke Awareness Month. Let me tell you a secret. I am a stroke survivor. It’s been more than 10 years since my life changed in the blink of an eye. My recovery took years. However, I consider myself fortunate because I fought my way back. Now I…
Read more...
Stem cell research is controversial, little understood by both the public and the legislators who set the framework governing it. In this interview with The Life Sciences Report, Tory Williams of the Alabama Institute of Medicine (AIM) describes how her patient advocacy group is working with research institutes to advance…
Read more...
Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets. Shane Storey, head of research at Australia-based Wilson HTM Investment Group, observes that as the market value of…
Read more...
Small-cap companies like Organovo (ONVO) frequently go through a lot of ups and downs – particularly with regards to their share price. That said, the roller coaster Organovo’s been on over the last couple of years has been notably dramatic, even by the standards of the small-cap biotech space. I’ve…
Read more...
In America, it's almost impossible to avoid GMOs (genetically modified organisms) at the supermarket. Nearly 80% of all processed foods in the United States are genetically modified. And because the US doesn’t require food manufacturers to label GMO products, consumers often have no idea the products they are consuming are genetically modified. In…
Read more...
Taking a page out of Big Pharma's playbook—looking for likely takeout candidates—is a profitable way to approach small-cap biotechs as potential investments, especially since large caps with shrinking pipelines have an unquenchable hunger for good new drugs and technologies, and the resources to track those drugs and technologies down. In…
Read more...
Health care is a growing industry that doesn't show any signs of slowing down. If you haven't considered investing yet, now is a great time to start. Here are some important things to watch out for when investing in different health care companies. Biotech The market for biotech stock has…
Read more...
When Fed Chair Janet Yellen commented last July about biotechs whose valuations were “substantially stretched,” we took it with a grain of salt. High valuations in the space are normal, and after a very healthy correction last April, we thought the space still had room to run.  Now, however, we…
Read more...
Buyside analysts don't publish ratings and target prices for the public: Nearly all their notes, analyses and projections are top secret. However, in this interview with The Life Sciences Report, Wasatch Advisors' Jill Wahleithner breaks that tacit rule. Wahleithner, a former big pharma scientist, identifies three unusual biotechs with advanced…
Read more...
Page 1 of 51

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN